A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

Inclusion Criteria:

* Adults 18 years of age or older, or the minimum age of consent according to local regulations.
* Body mass index of at least 27 kg/m² at Screening.
* Currently meets American College of Rheumatology (ACR) Criteria for knee OA.
* Pain due to knee OA.
* Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3.
* Willingness to complete the required analgesic washout.
* History of at least 1 self-reported unsuccessful dietary effort to lose body weight.

HbA1c value at Screening of:

1. \<6.5% (48 mmol/mol) for participants without T2D
2. ≥6.5% (48 mmol/mol) and \<10.0% (86 mmol/mol) for participants with T2D

Exclusion Criteria

* Self-reported body weight increase or decrease greater than 5% within 90 days before Screening.
* For participants with T2D at Screening only:

  • Diabetic maculopathy, proliferative diabetic retinopathy, or severe non-proliferative diabetic retinopathy requiring immediate intervention
* Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease.
* Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
* Significant active or unstable psychiatric disorder.
* Condition or knee disorder that could confound assessment of target-knee pain
* Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study.
* Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment.
* Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo.
* Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.